<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="publisher-id">PONE-D-11-00905</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0019687</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Immunology</subject>
            <subj-group>
              <subject>Immune system</subject>
              <subj-group>
                <subject>Cytokines</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Immunity</subject>
              <subj-group>
                <subject>Aging and immunity</subject>
                <subject>Inflammation</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Immune cells</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Molecular cell biology</subject>
            <subj-group>
              <subject>Chromosome biology</subject>
              <subj-group>
                <subject>Telomeres</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Clinical immunology</subject>
            <subj-group>
              <subject>Immune system</subject>
              <subj-group>
                <subject>Cytokines</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Immunity</subject>
              <subj-group>
                <subject>Aging and immunity</subject>
                <subject>Inflammation</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Immune cells</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Immunology</subject>
          <subject>Cell Biology</subject>
        </subj-group>
      </article-categories><title-group><article-title>Cumulative Inflammatory Load Is Associated with Short Leukocyte
                    Telomere Length in the Health, Aging and Body Composition Study</article-title><alt-title alt-title-type="running-head">Inflammation and Telomere
                    Length</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>O'Donovan</surname>
            <given-names>Aoife</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Pantell</surname>
            <given-names>Matthew S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Puterman</surname>
            <given-names>Eli</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Dhabhar</surname>
            <given-names>Firdaus S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Blackburn</surname>
            <given-names>Elizabeth H.</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Yaffe</surname>
            <given-names>Kristine</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Cawthon</surname>
            <given-names>Richard M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff8">
            <sup>8</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Opresko</surname>
            <given-names>Patricia L.</given-names>
          </name>
          <xref ref-type="aff" rid="aff9">
            <sup>9</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Hsueh</surname>
            <given-names>Wen-Chi</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
          <xref ref-type="aff" rid="aff10">
            <sup>10</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Satterfield</surname>
            <given-names>Suzanne</given-names>
          </name>
          <xref ref-type="aff" rid="aff11">
            <sup>11</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Newman</surname>
            <given-names>Anne B.</given-names>
          </name>
          <xref ref-type="aff" rid="aff12">
            <sup>12</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Ayonayon</surname>
            <given-names>Hilsa N.</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Rubin</surname>
            <given-names>Susan M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Harris</surname>
            <given-names>Tamara B.</given-names>
          </name>
          <xref ref-type="aff" rid="aff13">
            <sup>13</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Epel</surname>
            <given-names>Elissa S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <collab xlink:type="simple">for the
                        Health Aging and Body Composition Study</collab>
        </contrib>
      </contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Psychiatry, University of
                    California San Francisco, San Francisco, California, United States of
                    America</addr-line>
            </aff><aff id="aff2"><label>2</label><addr-line>San Francisco Veterans Affairs Medical Center,
                    San Francisco, California, United States of America</addr-line>
            </aff><aff id="aff3"><label>3</label><addr-line>University of California, Berkeley-University
                    of California, San Francisco Joint Medical Program, Berkeley and San Francisco,
                    California, United States of America</addr-line>
            </aff><aff id="aff4"><label>4</label><addr-line>Department of Psychiatry and Behavioral
                    Sciences, Stanford University, Stanford, California, United States of
                    America</addr-line>
            </aff><aff id="aff5"><label>5</label><addr-line>Department of Biochemistry and Biophysics,
                    University of California San Francisco, San Francisco, California, United States
                    of America</addr-line>
            </aff><aff id="aff6"><label>6</label><addr-line>Department of Neurology, University of
                    California San Francisco, San Francisco, California, United States of
                    America</addr-line>
            </aff><aff id="aff7"><label>7</label><addr-line>Department of Epidemiology and Biostatistics,
                    University of California San Francisco, San Francisco, California, United States
                    of America</addr-line>
            </aff><aff id="aff8"><label>8</label><addr-line>Department of Human Genetics, University of
                    Utah, Salt Lake City, Utah, United States of America</addr-line>
            </aff><aff id="aff9"><label>9</label><addr-line>Department of Environmental and Occupational
                    Health, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of
                    America</addr-line>
            </aff><aff id="aff10"><label>10</label><addr-line>Department of Medicine, University of
                    California San Francisco, San Francisco, California, United States of
                    America</addr-line>
            </aff><aff id="aff11"><label>11</label><addr-line>Department of Preventive Medicine,
                    University of Tennessee, Memphis, Tennessee, United States of
                    America</addr-line>
            </aff><aff id="aff12"><label>12</label><addr-line>Department of Epidemiology, University of
                    Pittsburgh, Pittsburgh, Pennsylvania, United States of America</addr-line>
            </aff><aff id="aff13"><label>13</label><addr-line>Laboratory for Epidemiology, Demography and
                    Biometry, National Institute on Aging, Bethesda, Maryland, United States of
                    America</addr-line>
            </aff><contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Lichterfeld</surname>
            <given-names>Mathias</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group><aff id="edit1">Massachusetts General Hospital, United States of America</aff><author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">aoife.odonovan@ucsf.edu</email></corresp>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: AOD MP EHB EE. Analyzed the data: AOD
                        MP EP RC. Contributed reagents/materials/analysis tools: RC. Wrote the
                        paper: AOD MP EP FD EHB KY RC PLO W-CH SS ABN HNA SMR TBH EE. Interpretation
                        of data: AOD MP EP FD EHB KY PLO W-CH SS ABN TBH EE. Critical administrative
                        and technical support: HNA SMR.</p>
        </fn>
      <fn fn-type="conflict">
        <p>The authors have read the journal's policy and have the following conflicts
                    to declare. Drs. Epel and Blackburn are co-founders in a company measuring
                    telomere diagnostics, Telomere Health Inc. This does not alter the authors'
                    adherence to all the PLoS ONE policies on sharing data and materials. None of
                    the other authors have competing interests in relation to this work.</p>
      </fn></author-notes><pub-date pub-type="collection">
        <year>2011</year>
      </pub-date><pub-date pub-type="epub">
        <day>13</day>
        <month>5</month>
        <year>2011</year>
      </pub-date><volume>6</volume><issue>5</issue><elocation-id>e19687</elocation-id><history>
        <date date-type="received">
          <day>30</day>
          <month>12</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>4</day>
          <month>4</month>
          <year>2011</year>
        </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2011</copyright-year><license><license-p>This is an open-access article, free of all copyright, and may be
                freely reproduced, distributed, transmitted, modified, built upon, or otherwise used
                by anyone for any lawful purpose. The work is made available under the Creative
                Commons CC0 public domain dedication.</license-p></license></permissions><abstract>
        <sec>
          <title>Background</title>
          <p>Leukocyte telomere length (LTL) is an emerging marker of biological age.
                        Chronic inflammatory activity is commonly proposed as a promoter of
                        biological aging in general, and of leukocyte telomere shortening in
                        particular. In addition, senescent cells with critically short telomeres
                        produce pro-inflammatory factors. However, in spite of the proposed causal
                        links between inflammatory activity and LTL, there is little clinical
                        evidence in support of their covariation and interaction.</p>
        </sec>
        <sec>
          <title>Methodology/Principal Findings</title>
          <p>To address this issue, we examined if individuals with high levels of the
                        systemic inflammatory markers interleukin-6 (IL-6), tumor necrosis
                        factor-α (TNF-α) and C-reactive protein (CRP) had increased odds for
                        short LTL. Our sample included 1,962 high-functioning adults who
                        participated in the Health, Aging and Body Composition Study (age range:
                        70–79 years). Logistic regression analyses indicated that individuals
                        with high levels of either IL-6 or TNF-α had significantly higher odds
                        for short LTL. Furthermore, individuals with high levels of both IL-6 and
                        TNF-α had significantly higher odds for short LTL compared with those
                        who had neither high (OR = 0.52,
                        CI = 0.37–0.72), only IL-6 high
                        (OR = 0.57, CI = 0.39–0.83)
                        or only TNF-α high (OR = 0.67,
                        CI = 0.46–0.99), adjusting for a wide variety of
                        established risk factors and potential confounds. In contrast, CRP was not
                        associated with LTL.</p>
        </sec>
        <sec>
          <title>Conclusions/Significance</title>
          <p>Results suggest that cumulative inflammatory load, as indexed by the
                        combination of high levels of IL-6 and TNF-α, is associated with
                        increased odds for short LTL. In contrast, high levels of CRP were not
                        accompanied by short LTL in this cohort of older adults. These data provide
                        the first large-scale demonstration of links between inflammatory markers
                        and LTL in an older population.</p>
        </sec>
      </abstract><funding-group><funding-statement>The study was conducted on behalf of the Health, Aging and Body Composition
                    (Health ABC) Study and was funded by National Institutes of Health (NIH)
                    National Institute on Aging (NIA) grants AG-6-2101, AG-6-2103, AG-6-2106, and
                    AG021918. This work was also supported by the Intramural Research Program of the
                    NIH, NIA as well as by Society in Science: The Branco Weiss Fellowship (AOD).
                    The funders had no role in study design, data collection and analysis, decision
                    to publish, or preparation of the manuscript.</funding-statement></funding-group><counts>
        <page-count count="7"/>
      </counts></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Telomeres, the DNA-protein complexes that cap the ends of chromosomes and protect
                against genomic instability, contain variable-length tracts of telomeric DNA.
                Leukocyte telomere length (LTL) is increasingly recognized as an index of biological
                age that predicts incidence of age-related diseases <xref ref-type="bibr" rid="pone.0019687-Willeit1">[1]</xref>, <xref ref-type="bibr" rid="pone.0019687-Fitzpatrick1">[2]</xref>, as well as all-cause and
                disease-specific mortality in diverse cohorts of older adults <xref ref-type="bibr" rid="pone.0019687-Willeit1">[1]</xref>, <xref ref-type="bibr" rid="pone.0019687-FarzanehFar1">[3]</xref>, <xref ref-type="bibr" rid="pone.0019687-Epel1">[4]</xref>, <xref ref-type="bibr" rid="pone.0019687-Carrero1">[5]</xref>, <xref ref-type="bibr" rid="pone.0019687-Cawthon1">[6]</xref>. In fact, older adults with
                below average LTL have more than threefold increased risk for early mortality <xref ref-type="bibr" rid="pone.0019687-Epel1">[4]</xref>, <xref ref-type="bibr" rid="pone.0019687-Cawthon1">[6]</xref>. Long LTL is
                also a predictor of years of healthy living, an outcome that integrates
                self-perceived functional status and duration of survival <xref ref-type="bibr" rid="pone.0019687-Njajou1">[7]</xref>. Importantly, telomere
                shortening is not just an index, but also a potential mechanism underlying some
                aspects of biological aging because short telomere length can lead to cessation of
                mitosis with consequent loss of ability for cell replenishment and, in some cellular
                settings, genomic instability, end-to-end chromosome fusion, and apoptosis as well
                as harmful DNA damage signaling and mitochondrial dysfunction <xref ref-type="bibr" rid="pone.0019687-Blackburn1">[8]</xref>, <xref ref-type="bibr" rid="pone.0019687-Blackburn2">[9]</xref>, <xref ref-type="bibr" rid="pone.0019687-Sahin1">[10]</xref>, <xref ref-type="bibr" rid="pone.0019687-Jaskelioff1">[11]</xref>. Notwithstanding the
                utility of LTL in predicting mortality and longevity, there is little clinical
                evidence regarding modifiable factors associated with and potentially driving
                leukocyte telomere shortening.</p>
      <p>Inflammatory activity is frequently proposed as a contributor to biological aging in
                general, and leukocyte telomere shortening in particular <xref ref-type="bibr" rid="pone.0019687-Carrero1">[5]</xref>, <xref ref-type="bibr" rid="pone.0019687-Chung1">[12]</xref>, <xref ref-type="bibr" rid="pone.0019687-Chung2">[13]</xref>, <xref ref-type="bibr" rid="pone.0019687-Kinouchi1">[14]</xref>. Accumulating evidence
                suggests a causal role for inflammation in the pathogenesis of multiple age-related
                diseases including cancer, atherosclerosis, autoimmune disorders, diabetes, and
                neurodegenerative diseases <xref ref-type="bibr" rid="pone.0019687-Pradhan1">[15]</xref>, <xref ref-type="bibr" rid="pone.0019687-Libby1">[16]</xref>, <xref ref-type="bibr" rid="pone.0019687-WyssCoray1">[17]</xref>, <xref ref-type="bibr" rid="pone.0019687-Moss1">[18]</xref>, <xref ref-type="bibr" rid="pone.0019687-Harris1">[19]</xref>, <xref ref-type="bibr" rid="pone.0019687-Volpato1">[20]</xref>, <xref ref-type="bibr" rid="pone.0019687-Slattery1">[21]</xref>. Elevated inflammatory activity could accelerate
                leukocyte telomere shortening by promoting cell turnover and replicative senescence
                    <xref ref-type="bibr" rid="pone.0019687-Aviv1">[22]</xref>, and by
                inducing the release of reactive oxygen species that damage telomeric DNA via
                oxidative stress <xref ref-type="bibr" rid="pone.0019687-Jaiswal1">[23]</xref>. One complication is that inflammatory cytokines
                including tumor necrosis factor-α (TNF-α) can both inhibit and promote
                activity of telomerase <xref ref-type="bibr" rid="pone.0019687-Xu1">[24]</xref>, <xref ref-type="bibr" rid="pone.0019687-Parish1">[25]</xref>, <xref ref-type="bibr" rid="pone.0019687-Akiyama1">[26]</xref>, the cellular enzyme primarily responsible for
                lengthening telomeres <xref ref-type="bibr" rid="pone.0019687-Greider1">[27]</xref>. On the other hand, <italic>in vitro</italic> research on
                various cell types, but not including normal leukocytes, indicates that an
                accumulation of senescent cells with critically short LTL may produce
                pro-inflammatory factors <xref ref-type="bibr" rid="pone.0019687-Rodier1">[28]</xref>, <xref ref-type="bibr" rid="pone.0019687-Krtolica1">[29]</xref>, hich could in turn contribute to an increased
                inflammatory load.</p>
      <p>Observations of short LTL in small samples of patients with inflammatory diseases
                including hepatitis C, liver cirrhosis, chronic kidney disease and chronic
                obstructive pulmonary disease provide preliminary support for the proposal that
                inflammation accelerates leukocyte telomere shortening <xref ref-type="bibr" rid="pone.0019687-Carrero1">[5]</xref>, <xref ref-type="bibr" rid="pone.0019687-Kinouchi1">[14]</xref>, <xref ref-type="bibr" rid="pone.0019687-Aikata1">[30]</xref>, <xref ref-type="bibr" rid="pone.0019687-Steer1">[31]</xref>. Specifically, in these studies,
                patients with inflammatory disorders exhibited shorter LTL cross-sectionally
                compared with healthy individuals <xref ref-type="bibr" rid="pone.0019687-Steer1">[31]</xref>, <xref ref-type="bibr" rid="pone.0019687-Houben1">[32]</xref>, and shorter telomeres in cells proximal to
                disease-related inflammatory activity <xref ref-type="bibr" rid="pone.0019687-Kinouchi1">[14]</xref>, <xref ref-type="bibr" rid="pone.0019687-Aikata1">[30]</xref>. Additionally, elevations in
                disease-specific and systemic inflammatory markers have been associated with short
                LTL in patients <xref ref-type="bibr" rid="pone.0019687-Carrero1">[5]</xref>. Although there are plausible pathways by which
                inflammation could accelerate telomere shortening even in adults without chronic
                disease, little is known about <italic>in vivo</italic> relationships between
                markers of inflammation and LTL in healthy older adults.</p>
      <p>In the present study, we examined if elevated inflammatory activity, indexed by high
                levels of the systemic inflammatory cytokines interleukin-6 (IL-6) and TNF-α and
                the acute phase protein C-reactive protein (CRP), is associated with increased risk
                for short LTL in the ‘Health, Aging and Body Composition’ (Health ABC)
                cohort, a large sample of well-functioning men and women aged 70–79 years. Our
                sample included 1,962 Health ABC participants who had complete data available for
                our primary analyses. We hypothesized that participants with high levels of IL-6
                and/or TNF-α and/or CRP would be more likely than participants with lower levels
                of these inflammatory markers to have short LTL, and that the combination of high
                IL-6, high TNF-α and high CRP, as an index of a high cumulative inflammatory
                load, would confer the greatest odds for short LTL.</p>
    </sec>
    <sec id="s2">
      <title>Results</title>
      <p>In spite of the restricted age range of the sample, age was significantly associated
                with shorter LTL (<italic>r</italic> = −.07,
                    <italic>p</italic> = .002) and higher levels of TNF-α
                    (<italic>r</italic> = .07,
                <italic>p</italic> = .003). However, age was negatively
                associated with levels of CRP (<italic>r</italic> = −.07,
                    <italic>p</italic> = .001) and was not associated with
                levels of IL-6 (<italic>r</italic> = .03,
                <italic>p</italic> = .19). Inflammatory markers were
                significantly and positively associated with one another. However, while the effect
                size for the relationship between IL-6 and CRP was medium to large
                    (<italic>r</italic> = .47, <italic>p</italic>&lt;.001),
                relationships between IL-6 and TNF-α
                (<italic>r</italic> = .27, <italic>p</italic>&lt;.001) as well
                as between TNF-α and CRP (<italic>r</italic> = .11,
                    <italic>p</italic>&lt;.001) had smaller effect sizes. <xref ref-type="table" rid="pone-0019687-t001">Table 1</xref> summarizes the baseline characteristics
                of the study population stratified by LTL tertile. As predicted, participants in the
                bottom tertile for LTL had the highest level of IL-6 and TNF-α, but there were
                no differences between groups in levels of CRP.</p>
      <table-wrap id="pone-0019687-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0019687.t001</object-id><label>Table 1</label><caption>
          <title>Sample characteristics by leukocyte telomere length (LTL)
                        tertile.</title>
        </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pone-0019687-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0019687.t001" xlink:type="simple"/><table>
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="3" rowspan="1">LTL Tertile</td>
              <td align="left" colspan="1" rowspan="1"/>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">Short</td>
              <td align="left" colspan="1" rowspan="1">Middle</td>
              <td align="left" colspan="1" rowspan="1">Long</td>
              <td align="left" colspan="1" rowspan="1">
                <italic>p value</italic>
              </td>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" colspan="1" rowspan="1">LTL (base pairs)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">≤4260</td>
              <td align="left" colspan="1" rowspan="1">4261–5280</td>
              <td align="left" colspan="1" rowspan="1">&gt;5280</td>
              <td align="left" colspan="1" rowspan="1"/>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Age (years), M (SD)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">74.0 (2.8)</td>
              <td align="left" colspan="1" rowspan="1">73.5 (2.9)</td>
              <td align="left" colspan="1" rowspan="1">73.4 (2.9)</td>
              <td align="left" colspan="1" rowspan="1">&lt;.01**</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Race (Black), n (%)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">239 (36.5)</td>
              <td align="left" colspan="1" rowspan="1">274 (41.8)</td>
              <td align="left" colspan="1" rowspan="1">271 (41.6)</td>
              <td align="left" colspan="1" rowspan="1">.09</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Sex (female), n (%)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">255 (39.0)</td>
              <td align="left" colspan="1" rowspan="1">330 (50.3)</td>
              <td align="left" colspan="1" rowspan="1">398 (61.0)</td>
              <td align="left" colspan="1" rowspan="1">&lt;.01**</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Site (Memphis), n (%)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">324 (49.5)</td>
              <td align="left" colspan="1" rowspan="1">367 (56.0)</td>
              <td align="left" colspan="1" rowspan="1">293 (44.9)</td>
              <td align="left" colspan="1" rowspan="1">&lt;.01**</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Body mass index (kg/m<sup>2</sup>)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">27.6 (4.8)</td>
              <td align="left" colspan="1" rowspan="1">27.4 (4.9)</td>
              <td align="left" colspan="1" rowspan="1">27.3 (4.7)</td>
              <td align="left" colspan="1" rowspan="1">.59</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Smoking status, n (%)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">Current</td>
              <td align="left" colspan="1" rowspan="1">72 (11.0)</td>
              <td align="left" colspan="1" rowspan="1">73 (11.1)</td>
              <td align="left" colspan="1" rowspan="1">66 (10.1)</td>
              <td align="left" colspan="1" rowspan="1"/>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">Former</td>
              <td align="left" colspan="1" rowspan="1">319 (48.8)</td>
              <td align="left" colspan="1" rowspan="1">305 (46.5)</td>
              <td align="left" colspan="1" rowspan="1">270 (41.4)</td>
              <td align="left" colspan="1" rowspan="1"/>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">Never</td>
              <td align="left" colspan="1" rowspan="1">263 (40.2)</td>
              <td align="left" colspan="1" rowspan="1">278 (42.4)</td>
              <td align="left" colspan="1" rowspan="1">316 (48.5)</td>
              <td align="left" colspan="1" rowspan="1">.04*</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Sleep (hours/night)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">6.9 (1.3)</td>
              <td align="left" colspan="1" rowspan="1">6.9 (1.4)</td>
              <td align="left" colspan="1" rowspan="1">6.8 (1.3)</td>
              <td align="left" colspan="1" rowspan="1">.79</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Alcohol (drinks/week), n (%)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">0</td>
              <td align="left" colspan="1" rowspan="1">303 (46.3)</td>
              <td align="left" colspan="1" rowspan="1">333 (50.7)</td>
              <td align="left" colspan="1" rowspan="1">328 (50.3)</td>
              <td align="left" colspan="1" rowspan="1"/>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">&lt;1</td>
              <td align="left" colspan="1" rowspan="1">142 (21.7)</td>
              <td align="left" colspan="1" rowspan="1">144 (22.0)</td>
              <td align="left" colspan="1" rowspan="1">129 (19.8)</td>
              <td align="left" colspan="1" rowspan="1"/>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">1–7</td>
              <td align="left" colspan="1" rowspan="1">160 (24.5)</td>
              <td align="left" colspan="1" rowspan="1">135 (20.6)</td>
              <td align="left" colspan="1" rowspan="1">142 (21.8)</td>
              <td align="left" colspan="1" rowspan="1"/>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">&gt;7</td>
              <td align="left" colspan="1" rowspan="1">49 (7.5)</td>
              <td align="left" colspan="1" rowspan="1">44 (6.7)</td>
              <td align="left" colspan="1" rowspan="1">53 (8.1)</td>
              <td align="left" colspan="1" rowspan="1">.46</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Exercise (kcal/kg/week)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">85.9 (73.5)</td>
              <td align="left" colspan="1" rowspan="1">85.7 (73.1)</td>
              <td align="left" colspan="1" rowspan="1">82.6 (64.0)</td>
              <td align="left" colspan="1" rowspan="1">.93</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Chronic condition, n (%)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">444 (67.9)</td>
              <td align="left" colspan="1" rowspan="1">448 (68.2)</td>
              <td align="left" colspan="1" rowspan="1">464 (71.2)</td>
              <td align="left" colspan="1" rowspan="1">.38</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Recent infection, n (%)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">43 (6.6)</td>
              <td align="left" colspan="1" rowspan="1">46 (7.0)</td>
              <td align="left" colspan="1" rowspan="1">52 (8.0)</td>
              <td align="left" colspan="1" rowspan="1">.61</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Anti-inflammatory medications, n (%)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">344 (52.6)</td>
              <td align="left" colspan="1" rowspan="1">356 (54.3)</td>
              <td align="left" colspan="1" rowspan="1">332 (50.9)</td>
              <td align="left" colspan="1" rowspan="1">.48</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Statins, n (%)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">89 (13.6)</td>
              <td align="left" colspan="1" rowspan="1">79 (12.0)</td>
              <td align="left" colspan="1" rowspan="1">97 (14.9)</td>
              <td align="left" colspan="1" rowspan="1">.32</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Income, n (%)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">&lt;10 k</td>
              <td align="left" colspan="1" rowspan="1">68 (10.4)</td>
              <td align="left" colspan="1" rowspan="1">86 (13.1)</td>
              <td align="left" colspan="1" rowspan="1">88 (13.5)</td>
              <td align="left" colspan="1" rowspan="1"/>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">10 k–25 k</td>
              <td align="left" colspan="1" rowspan="1">262 (40.0)</td>
              <td align="left" colspan="1" rowspan="1">272 (41.5)</td>
              <td align="left" colspan="1" rowspan="1">242 (37.1)</td>
              <td align="left" colspan="1" rowspan="1"/>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">25 k–50 k</td>
              <td align="left" colspan="1" rowspan="1">217 (33.2)</td>
              <td align="left" colspan="1" rowspan="1">205 (31.3)</td>
              <td align="left" colspan="1" rowspan="1">218 (33.4)</td>
              <td align="left" colspan="1" rowspan="1"/>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">&gt;50 k</td>
              <td align="left" colspan="1" rowspan="1">107 (16.4)</td>
              <td align="left" colspan="1" rowspan="1">93 (14.2)</td>
              <td align="left" colspan="1" rowspan="1">104 (16.0)</td>
              <td align="left" colspan="1" rowspan="1">.38</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Education, n (%)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1"/>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">&lt;HS</td>
              <td align="left" colspan="1" rowspan="1">156 (23.9)</td>
              <td align="left" colspan="1" rowspan="1">166 (25.3)</td>
              <td align="left" colspan="1" rowspan="1">123 (18.9)</td>
              <td align="left" colspan="1" rowspan="1"/>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">HS</td>
              <td align="left" colspan="1" rowspan="1">191 (29.2)</td>
              <td align="left" colspan="1" rowspan="1">184 (28.1)</td>
              <td align="left" colspan="1" rowspan="1">186 (28.4)</td>
              <td align="left" colspan="1" rowspan="1"/>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">&gt;HS</td>
              <td align="left" colspan="1" rowspan="1">307 (46.9)</td>
              <td align="left" colspan="1" rowspan="1">306 (46.7)</td>
              <td align="left" colspan="1" rowspan="1">343 (52.6)</td>
              <td align="left" colspan="1" rowspan="1">.05*</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Interleukin-6: Mdn (IQR)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">1.9 (1.3–3.0)</td>
              <td align="left" colspan="1" rowspan="1">1.8 (1.3–2.8)</td>
              <td align="left" colspan="1" rowspan="1">1.7 (1.2–4.5)</td>
              <td align="left" colspan="1" rowspan="1">.05*</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Tumor necrosis factor-α: Mdn (IQR)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">3.4 (2.7–4.4)</td>
              <td align="left" colspan="1" rowspan="1">3.2 (2.5–4.1)</td>
              <td align="left" colspan="1" rowspan="1">3.0 (2.3–3.8)</td>
              <td align="left" colspan="1" rowspan="1">&lt;.01**</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">C-reactive protein: Mdn (IQR)</td>
              <td align="left" colspan="1" rowspan="1"/>
              <td align="left" colspan="1" rowspan="1">1.6 (1.0–3.0)</td>
              <td align="left" colspan="1" rowspan="1">1.6 (0.9–3.0)</td>
              <td align="left" colspan="1" rowspan="1">1.74 (1.0–3.3)</td>
              <td align="left" colspan="1" rowspan="1">.17</td>
            </tr>
          </tbody>
        </table></alternatives><table-wrap-foot>
          <fn id="nt101">
            <label/>
            <p>Notes. HS = high school;
                            IQR = interquartile range;
                            LTL = leukocyte telomere length;
                            M = mean; Mdn = Median;
                            n = number of participants;
                            SD = standard deviation; p-values for comparisons
                            of means were calculated using one-way ANCOVA tests for continuous
                            variables, and chi-squared tests for categorical variables. One-way
                            ANCOVAs were calculated using log-transformed values because variances
                            were not equal between groups. However, reported means and medians are
                            based on raw data.</p>
          </fn>
        </table-wrap-foot></table-wrap>
      <sec id="s2a">
        <title>Inflammatory Activity and LTL</title>
        <p>In our primary analytic model, we found that the odds of having short LTL (i.e.,
                    LTL in the bottom tertile or ≤4260 bp) were significantly higher for those
                    participants who had high (i.e., top tertile) levels of either IL-6 (≥2.39
                    pg/mL), TNF-α (≥3.72 pg/mL) or CRP (≥2.51 mg/L). In these analyses,
                    the results of which are summarized in <xref ref-type="table" rid="pone-0019687-t002">Table 2</xref>, groups were not mutually exclusive,
                    such that the same individual could be represented in multiple groups if he or
                    she had high levels of IL-6, TNF-α and CRP. Adjusting for a wide range of
                    potential confounds and covariates, the odds for short LTL were significantly
                    higher in those who had either IL-6 levels in the top tertile
                    (OR = 1.3, 95%
                    CI = 1.1–1.7) or TNF-α levels in the top tertile
                    (OR = 1.5, 95%
                    CI = 1.2–1.9). The highest odds for short LTL were
                    observed in those participants who had high levels of both IL-6 and TNF-α
                    (OR = 1.8, CI = 1.3–2.4). In
                    contrast, the addition of high levels of CRP did not confer increased odds for
                    short LTL, as indexed by the lack of association between CRP and LTL
                    (OR = 1.1, 95%
                    CI = 08–1.4), and by the roughly equal odds of having
                    short LTL for those who had high levels of CRP in addition to high levels of
                    IL-6 and TNF-α (OR = 1.7,
                    CI = 1.1–2.6).</p>
        <table-wrap id="pone-0019687-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0019687.t002</object-id><label>Table 2</label><caption>
            <title>Systemic inflammatory markers as predictors of short leukocyte
                            telomere length.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pone-0019687-t002-2" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0019687.t002" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="2" rowspan="1">Unadjusted</td>
                <td align="left" colspan="2" rowspan="1">Adjusted for age, gender and race</td>
                <td align="left" colspan="2" rowspan="1">Adjusted for all covariates</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">OR</td>
                <td align="left" colspan="1" rowspan="1">(95% CI)</td>
                <td align="left" colspan="1" rowspan="1">OR</td>
                <td align="left" colspan="1" rowspan="1">(95% CI)</td>
                <td align="left" colspan="1" rowspan="1">OR</td>
                <td align="left" colspan="1" rowspan="1">(95% CI)</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">IL-6</td>
                <td align="left" colspan="1" rowspan="1">1.3</td>
                <td align="left" colspan="1" rowspan="1">(1.0–1.6)<xref ref-type="table-fn" rid="nt103">*</xref></td>
                <td align="left" colspan="1" rowspan="1">1.3</td>
                <td align="left" colspan="1" rowspan="1">(1.0–1.6)<xref ref-type="table-fn" rid="nt103">*</xref></td>
                <td align="left" colspan="1" rowspan="1">1.3</td>
                <td align="left" colspan="1" rowspan="1">(1.0–1.7)<xref ref-type="table-fn" rid="nt103">*</xref></td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">TNF-α</td>
                <td align="left" colspan="1" rowspan="1">1.6</td>
                <td align="left" colspan="1" rowspan="1">(1.3–2.1)<xref ref-type="table-fn" rid="nt104">**</xref></td>
                <td align="left" colspan="1" rowspan="1">1.5</td>
                <td align="left" colspan="1" rowspan="1">(1.2–1.91)<xref ref-type="table-fn" rid="nt104">**</xref></td>
                <td align="left" colspan="1" rowspan="1">1.5</td>
                <td align="left" colspan="1" rowspan="1">(1.2–1.9)<xref ref-type="table-fn" rid="nt104">**</xref></td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">CRP</td>
                <td align="left" colspan="1" rowspan="1">0.9</td>
                <td align="left" colspan="1" rowspan="1">(0.7–1.1)</td>
                <td align="left" colspan="1" rowspan="1">1.1</td>
                <td align="left" colspan="1" rowspan="1">(0.86–1.4)</td>
                <td align="left" colspan="1" rowspan="1">1.1</td>
                <td align="left" colspan="1" rowspan="1">(0.8–1.4)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">IL-6+TNF-α</td>
                <td align="left" colspan="1" rowspan="1">1.9</td>
                <td align="left" colspan="1" rowspan="1">(1.4–2.6)<xref ref-type="table-fn" rid="nt104">**</xref></td>
                <td align="left" colspan="1" rowspan="1">1.7</td>
                <td align="left" colspan="1" rowspan="1">(1.3–2.4)<xref ref-type="table-fn" rid="nt104">**</xref></td>
                <td align="left" colspan="1" rowspan="1">1.8</td>
                <td align="left" colspan="1" rowspan="1">(1.3–2.4)<xref ref-type="table-fn" rid="nt104">**</xref></td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">IL-6+CRP</td>
                <td align="left" colspan="1" rowspan="1">1.1</td>
                <td align="left" colspan="1" rowspan="1">(0.9–1.5)</td>
                <td align="left" colspan="1" rowspan="1">1.3</td>
                <td align="left" colspan="1" rowspan="1">(0.9–1.7)</td>
                <td align="left" colspan="1" rowspan="1">1.3</td>
                <td align="left" colspan="1" rowspan="1">(0.9–1.7)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">TNF-α+CRP</td>
                <td align="left" colspan="1" rowspan="1">1.6</td>
                <td align="left" colspan="1" rowspan="1">(1.2–2.2)<xref ref-type="table-fn" rid="nt104">**</xref></td>
                <td align="left" colspan="1" rowspan="1">1.7</td>
                <td align="left" colspan="1" rowspan="1">(1.2–2.4)<xref ref-type="table-fn" rid="nt104">**</xref></td>
                <td align="left" colspan="1" rowspan="1">1.7</td>
                <td align="left" colspan="1" rowspan="1">(1.2–2.4)<xref ref-type="table-fn" rid="nt104">**</xref></td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">IL-6+TNF-α+CRP</td>
                <td align="left" colspan="1" rowspan="1">1.7</td>
                <td align="left" colspan="1" rowspan="1">(1.2–2.5)<xref ref-type="table-fn" rid="nt104">**</xref></td>
                <td align="left" colspan="1" rowspan="1">1.7</td>
                <td align="left" colspan="1" rowspan="1">(1.1–2.5)<xref ref-type="table-fn" rid="nt104">**</xref></td>
                <td align="left" colspan="1" rowspan="1">1.7</td>
                <td align="left" colspan="1" rowspan="1">(1.1–2.6)<xref ref-type="table-fn" rid="nt104">**</xref></td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt102">
              <label/>
              <p>Notes.</p>
            </fn>
            <fn id="nt103">
              <label/>
              <p>*indicates <italic>p</italic>&lt;.05 and</p>
            </fn>
            <fn id="nt104">
              <label/>
              <p>**indicates <italic>p</italic>&lt;.01;</p>
            </fn>
            <fn id="nt105">
              <label/>
              <p>OR refers to odds ratio based on logistic regression; 95% CI
                                is the 95% confidence interval;
                                IL-6 = Interleukin-6;
                                TNF-α = Tumor necrosis factor-α;
                                CRP = C-reactive protein.</p>
            </fn>
          </table-wrap-foot></table-wrap>
        <p>We additionally ran the same models using the established high-risk clinical
                    cutoff (&gt;3 mg/L) for CRP <xref ref-type="bibr" rid="pone.0019687-Pearson1">[33]</xref>. While individuals who had CRP above this clinical
                    cutoff had marginally higher odds for short LTL, this was not significant in any
                    of the models, including when we only adjusted for telomere batch
                    (OR = 1.3, CI = 1.0–1.7). Thus,
                    individuals with CRP in either the top tertile in the sample or above the
                    recognized clinical cutoff did not appear to have significantly increased odds
                    for short LTL.</p>
        <p>To further examine the observed associations of IL-6 and TNF-α with short LTL
                    and to compare mutually exclusive groups instead of potentially overlapping
                    groups, we excluded CRP from our model and compared the odds for short LTL among
                    four mutually exclusive groups of participants: those with both high IL-6 and
                    high TNF-α; only high IL-6; only high TNF-α; and neither high IL-6 nor
                    high TNF-α. These analyses were conducted while statistically controlling
                    for established risk factors and potential confounds and with both high IL-6 and
                    high TNF-α as our reference group. Results indicated that the combination of
                    both high IL-6 and high TNF-α levels was associated with roughly double the
                    odds for short LTL compared with having neither high IL-6 nor high TNF-α
                    (OR = 0.52, CI = 0.37–0.72).
                    Furthermore, the combination of high IL-6 and high TNF-α was associated with
                    significantly higher odds for short LTL compared with having only IL-6 high
                    (OR = 0.57, CI = 0.39–0.83) or
                    only TNF-α high (OR = 0.67,
                    CI = 0.46–0.99). Finally, mean LTL adjusted for site,
                    age, gender, and race was 201 base pairs shorter in participants with high
                    levels of both IL-6 and TNF-α
                    (<italic>M</italic> = 4701.93 bp,
                    <italic>SE</italic> = 68.07) compared with that of
                    participants who did not have high levels of both of these
                    (<italic>M</italic> = 4902.21 bp,
                    <italic>SE</italic> = 28.20), and this difference in
                    absolute LTL was significant,
                    <italic>F</italic>(1,1937) = 7.35,
                    <italic>p</italic> = .007.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Discussion</title>
      <p>Short LTL, a potential index of biological age, is associated with increased risk for
                age-related diseases as well as early all-cause and disease-specific mortality <xref ref-type="bibr" rid="pone.0019687-FarzanehFar1">[3]</xref>, <xref ref-type="bibr" rid="pone.0019687-Epel1">[4]</xref>, <xref ref-type="bibr" rid="pone.0019687-Carrero1">[5]</xref>, <xref ref-type="bibr" rid="pone.0019687-Cawthon1">[6]</xref>. The present
                research study is to date the largest to demonstrate an association between elevated
                inflammatory activity and short LTL. Moreover, the present study is the first to
                indicate that the combination of high IL-6 and TNF-α is associated with
                increased odds for short LTL, over and above the odds associated with having high
                levels of only one of these markers. Of note, having high levels of both IL-6 and
                TNF-α conferred almost twice the odds of being in the bottom tertile for LTL
                compared with having lower levels of both markers. In contrast, having high levels
                of CRP, as indexed by CRP levels either in the top tertile for the sample or above
                the established clinical cutoff, was not associated with increased odds for short
                LTL. Importantly, all of our results held when controlling for the contribution of
                numerous established risk factors for short LTL and potential confounds. Together
                with the observed causal relationships between inflammatory activity and LTL in
                animal and <italic>in vitro</italic> studies, these data provide preliminary
                evidence that adjunct anti-inflammatory therapies could potentially prevent
                accelerated leukocyte telomere shortening or protect against the negative effects of
                short LTL in older adults.</p>
      <p>We included IL-6, TNF-α and CRP as three separate measures of systemic
                inflammatory activity in our study. Although all of these inflammatory markers were
                significantly correlated with one another, relationships between them were not
                strong (<italic>r</italic>'s≤.47). IL-6 and CRP were the most strongly
                associated of the inflammatory markers, sharing 22% of variance. Given that
                IL-6 is a major inducer of CRP production by hepatocytes <xref ref-type="bibr" rid="pone.0019687-Castell1">[34]</xref>, <xref ref-type="bibr" rid="pone.0019687-Castell2">[35]</xref>, the larger effect size for
                the relationship between these markers is not unexpected. However, high levels of
                IL-6, but not high levels of CRP, were associated with increased odds of short LTL
                in the sample. There is evidence that IL-6 is necessary but not sufficient to induce
                CRP synthesis <xref ref-type="bibr" rid="pone.0019687-Weinhold1">[36]</xref>, and also evidence that human coronary artery smooth
                muscle cells may produce CRP and that IL-6 is not a necessary inducer of CRP
                synthesis by these cells <xref ref-type="bibr" rid="pone.0019687-Calabro1">[37]</xref>. Thus, although IL-6 is an inducer of CRP and their
                concentrations are correlated, the physiological actions of IL-6 and CRP are not
                expected to be identical. The present findings, which need to be further
                investigated, suggest that in the case of LTL, these two factors do not have the
                same effects. Notably with regard to our overall findings, IL-6 and TNF-α shared
                only 7% of variance, supporting the formulation that circulating levels of
                these cytokines reflect different aspects of the inflammatory response. Thus, while
                each of these cytokines may contribute to leukocyte telomere shortening by promoting
                cell turnover and replicative senescence, inducing oxidative stress, and regulating
                telomerase activity <xref ref-type="bibr" rid="pone.0019687-Aviv1">[22]</xref>, <xref ref-type="bibr" rid="pone.0019687-Jaiswal1">[23]</xref>, <xref ref-type="bibr" rid="pone.0019687-Xu1">[24]</xref>, <xref ref-type="bibr" rid="pone.0019687-Parish1">[25]</xref>, <xref ref-type="bibr" rid="pone.0019687-Akiyama1">[26]</xref>, chronic exposure to the cumulative load of both high
                IL-6 and high TNF-α may have the greatest impact on the rate of leukocyte
                telomere shortening.</p>
      <p>Equally plausible, however, is the emerging hypothesis that participants with short
                LTL in our study had the greatest proportion of accumulated senescent bodily cells
                overall, including fibroblasts and epithelial cells, which could plausibly
                contribute to the observed higher levels of IL-6 and TNF-α in this group <xref ref-type="bibr" rid="pone.0019687-Rodier1">[28]</xref>, <xref ref-type="bibr" rid="pone.0019687-Coppe1">[38]</xref>. Given that
                TNF-α and IL-6 may inhibit programmed cell death in specific cell types <xref ref-type="bibr" rid="pone.0019687-Lin1">[39]</xref>, <xref ref-type="bibr" rid="pone.0019687-Mangan1">[40]</xref>, high levels of
                these cytokines could even contribute to the maintenance of senescent cells in the
                system and hence the continued production of pro-inflammatory factors. However, the
                cross-sectional design of our study precludes drawing conclusions about the causal
                direction in the relationship between inflammatory activity and LTL.</p>
      <p>In previous research, the cumulative load of high IL-6, high TNF-α and high CRP
                was found to confer the greatest risk for cardiovascular events in the Health ABC
                cohort <xref ref-type="bibr" rid="pone.0019687-Njajou1">[7]</xref>.
                However, CRP did not likewise contribute to the predictive value of the inflammatory
                markers with regard to LTL. Our finding of no association between CRP and LTL is in
                line with a previous finding of no associations between CRP and LTL in
                post-menopausal women, and in ‘Cardiovascular Health Study’ participants
                who were older than 73 years <xref ref-type="bibr" rid="pone.0019687-Njajou1">[7]</xref>. However, this finding does not support our hypothesis
                that higher levels of all measures of inflammatory activity would be associated with
                shorter LTL. Previous research has demonstrated that although CRP is reliably
                associated with cardiovascular disease (CVD) outcomes, CRP does not appear to be
                causally involved in the development of CVD <xref ref-type="bibr" rid="pone.0019687-Elliott1">[41]</xref>. Furthermore, CRP is less
                predictive of CVD in older compared with younger adults <xref ref-type="bibr" rid="pone.0019687-Kritchevsky1">[42]</xref>, <xref ref-type="bibr" rid="pone.0019687-Cesari1">[43]</xref> and CRP levels were not
                predictive of cardiovascular events in a sample of high-risk Japanese adults in whom
                IL-6 was an independent predictor of such events <xref ref-type="bibr" rid="pone.0019687-Nishida1">[44]</xref>. However, it is possible that
                CRP would be associated with LTL in older populations with other diseases, such as
                inflammatory diseases characterized by very high levels of CRP. Our findings in
                relation to CRP may have particular relevance in clinical settings where CRP is the
                most commonly used index of inflammatory activity because they suggest that
                pro-inflammatory cytokine concentrations may serve as complementary indices of
                inflammation.</p>
      <p>The present findings must be interpreted in the context of several limitations.
                First, the cross-sectional design of the present study precludes causal
                interpretations. Second, the narrow age range of our sample of older adults
                (70–79 years) is both a strength and weakness of our study. While this narrow
                age range allows us to maximize power to detect associations between inflammatory
                activity and LTL without many of the confounding factors associated with a sample of
                wider age range (e.g., cohort effects, hormonal effects), the findings of the
                present study may not be generalizable to other stages of the lifespan. Moreover,
                anti-inflammatory medications were common in our sample of older adults. Given the
                wide range of medications that have anti-inflammatory effects and the variability in
                dosage across individuals, our statistical control for anti-inflammatory medications
                is likely to be insufficient but is the best option currently available. There has
                been debate about the relative merits of different methods used to assay LTL and the
                Q-PCR method has been subject to criticism <xref ref-type="bibr" rid="pone.0019687-Aviv2">[45]</xref>, <xref ref-type="bibr" rid="pone.0019687-Aviv3">[46]</xref>. However, strong associations
                between LTL as assessed by the Southern blot method and Q-PCR method have been
                documented <xref ref-type="bibr" rid="pone.0019687-Cawthon2">[47]</xref>,
                and the coefficient of variation of the LTL assay for this study was low at
                4%. In addition, some findings related to LTL in Health ABC have been
                replicated in a cohort who had LTL measured with the traditional Southern blot
                technique <xref ref-type="bibr" rid="pone.0019687-Njajou2">[48]</xref>.
                Finally, it should be noted that effect sizes were small in this study and caution
                is therefore advised in the interpretation of the results pending future studies in
                independent cohorts.</p>
      <p>Data from this large cohort of older adults indicates links between inflammatory
                activity and biological aging. In particular, the present data indicate that the
                cumulative load of high IL-6 and high TNF-α is accompanied by increased risk for
                short LTL. The present data also replicate a previous finding of no association
                between CRP and LTL in older adults, and suggest that systemic inflammatory
                cytokines may have more relevance to leukocyte telomere shortening than the more
                commonly used inflammatory marker CRP. In sum, older adults with high levels of
                inflammatory activity may be at increased risk for accelerated leukocyte telomere
                shortening, and those with short LTL may have increased risk for diseases with an
                inflammatory etiology.</p>
    </sec>
    <sec id="s4" sec-type="methods">
      <title>Methods</title>
      <sec id="s4a">
        <title>Study Population</title>
        <p>Study participants for this investigation included 1,962 well-functioning men and
                    women aged 70–79 years who participated in Health ABC. Participants were
                    identified from a random sample of white Medicare beneficiaries and all
                    age-eligible black community residents in designated ZIP code areas surrounding
                    Pittsburgh and Memphis. To be eligible for participation in Health ABC,
                    participants had to report no difficulty in walking one-quarter mile (0.5 km) or
                    climbing 10 stairs without resting. Exclusion criteria included reported
                    difficulty performing basic activities of daily living, obvious cognitive
                    impairment, inability to communicate with the interviewer, intention of moving
                    within 3 years, or participation in a trial involving a lifestyle intervention.
                    Additionally, of the 3.075 participants who took part in Health ABC, our sample
                    of 1,962 includes only participants who had complete data on LTL, inflammatory
                    markers and all covariates included in our analysis. Our sample was not
                    significantly different from excluded participants with missing data on age or
                    site, but they were less likely to be female (50.1% of subsample versus
                    54% of non-sample, <italic>p</italic> = .04) and
                    less likely to be Black (40% of subsample versus 44.7% of
                    non-sample, <italic>p</italic> = .01). All participants
                    gave written informed consent. The Institutional Review Boards at the University
                    of Pittsburgh, the University of Tennessee and the University of California, San
                    Francisco approved the protocol. Baseline data were collected from 1997 to
                    1998.</p>
      </sec>
      <sec id="s4b">
        <title>LTL Measurement</title>
        <p>Quantitative polymerase chain reaction (Q-PCR) was used to measure LTL in the
                    genomic DNA of peripheral leukocytes by determining the ratio of telomere repeat
                    copy number to single-copy gene copy number (T/S ratio) in study samples
                    relative to a reference sample <xref ref-type="bibr" rid="pone.0019687-Cawthon2">[47]</xref>, <xref ref-type="bibr" rid="pone.0019687-Cawthon3">[49]</xref>. The Q-PCR assay was conducted on three separate DNA
                    samples per participant, and average LTL was calculated as the mean value of
                    these triplicates. Each T/S value was later converted to number of base pairs
                    (bp) by multiplying the T/S value by the known LTL of the reference DNA, which
                    is a pooled sample of DNAs from several normal Utah whites aged 65 years and
                    older. The slope of the linear regression line through a plot of T/S ratio (the
                    x axis) versus mean TRF length (the y axis) is the number of base pairs of
                    telomeric DNA corresponding to a single T/S unit. All samples were measured in
                    triplicate and the mean value of the triplicates was used in analyses. The
                    coefficient of variation for this assay is 4% and results obtained with
                    the Q-PCR method are strongly associated with the traditional terminal
                    restriction fragment length index of LTL obtained by Southern blot technique
                        <xref ref-type="bibr" rid="pone.0019687-Cawthon2">[47]</xref>. DNA
                    was available for 2,880 of the 3,075 individuals who participated in Health ABC,
                    and LTL was successfully measured in 2,721 cases.</p>
      </sec>
      <sec id="s4c">
        <title>Inflammatory Markers</title>
        <p>Blood samples for inflammatory markers were obtained in the morning (median time
                    was 9:19 AM; interquartile range was from 8:49 AM to 9:52 AM). IL-6 and CRP
                    levels were measured in serum and TNF-α levels were measured in plasma.
                    Tubes for IL-6 and CRP were serum separator tubes containing no anticoagulant.
                    Tubes for TNF-α were citrated tubes containing 0.5 mL of 3.8% sodium
                    citrate. After processing, the specimens were aliquoted into cryovials, frozen
                    at −70°C, and shipped to the Core Laboratory at the University of
                    Vermont. Serum IL-6 levels and plasma TNF-α levels were measured in
                    duplicate by enzyme-linked immunosorbent assay (ELISA) kits from R&amp;D Systems
                    (Minneapolis, MN). The detectable limit for IL-6 (by HS600 Quantikine kit) was
                    .10 pg/mL, and for TNF-α (by HSTA50 kit) was .18 pg/mL. Plasma levels of CRP
                    were also measured in duplicate by ELISA based on purified protein and
                    polyclonal anti-CRP antibodies (Calbiochem, San Diego, CA). The CRP assay was
                    standardized according to the World Health Organization First International
                    Reference Standard, with a sensitivity of 0.08 µg/mL. Measures of IL-6,
                    TNF-α and CRP were missing for 162, 203, and 38 participants respectively.
                    Intra and inter-assay coefficients of variation for inflammatory markers were
                    respectively: 10% and 15% for IL-6; 16% and 15% for
                    TNF-α; and 8% and 5% for CRP.</p>
      </sec>
      <sec id="s4d">
        <title>Covariates</title>
        <p>Covariates were selected a priori based on previous research and included
                    characteristics associated with inflammatory markers and LTL in previous
                    research. Such a priori selection of covariates has been validated for logistic
                    regression procedures <xref ref-type="bibr" rid="pone.0019687-Steyerberg1">[50]</xref>, <xref ref-type="bibr" rid="pone.0019687-Sun1">[51]</xref>. The telomere batch number corresponds to a
                    particular run of the Q-PCR assay used to measure LTL. Because there is some
                    variability between assays, we controlled for telomere batch in all LTL
                    analyses, constructing a dummy variable for each batch to enter into regression
                    models. Sociodemographic covariates included study site, age, gender, and race,
                    as well as education (less than high school; high school; more than high school)
                    and income (&lt;$10 k; $10–25 k; $25–50 k;
                    &gt;$50 k). BMI was calculated as weight in kilograms divided by height
                    in meters squared. Behavioral factors including smoking status (current, former,
                    never), average alcohol use during the past year (0, &lt;1, 1–7 or &gt;7
                    drinks/week), exercise (total kilocalories burned per week) and hours of sleep
                    per night on average were assessed in the baseline interview. Participants were
                    asked whether they had experienced symptoms of respiratory infections within the
                    last 2 weeks. The baseline presence of chronic illnesses including lung disease,
                    heart disease (including myocardial infarction, angina pectoris, and congestive
                    heart failure), stroke, diabetes mellitus, broken hip, and arthritis was
                    adjudicated using standardized algorithms considering various sources of
                    information: self-report of a medical diagnosis, medication use, and results of
                    screening tests from a clinical examination where appropriate. All medications
                    regularly taken in the past 2 weeks were recorded and coded according to the
                    Iowa Drug Information System (IDIS) code <xref ref-type="bibr" rid="pone.0019687-Pahor1">[52]</xref>. Using this drug inventory,
                    the daily use of antiinflammatory drugs (IDIS codes 2808 or 5208) and statins
                    (IDIS code 2406) was assessed.</p>
        <p>Our primary models were run with three different sets of covariates. First,
                    adjusting only for telomere batch; second, adjusting for telomere batch, as well
                    as potential confounds including study site, age, gender and race; and third,
                    adjusting for telomere batch, as well as potential confounds and other potential
                    covariates including study site, age, gender, race, income, education, BMI,
                    smoking status, alcohol use, exercise, sleep, chronic disease, recent
                    respiratory illness, and the use of anti-inflammatory drugs or statins.</p>
      </sec>
      <sec id="s4e">
        <title>Statistical Analysis</title>
        <p>Logistic regression and analysis of covariance were used to test our primary
                    hypothesis that high levels of inflammatory activity would be associated with
                    increased odds for short LTL, as indexed by the odds of having LTL in the bottom
                    tertile in the sample and by LTL in base pairs, respectively. For the purpose of
                    these analyses, participants with values in the upper tertile of the sample were
                    classified as “high” for inflammatory markers and those with values
                    in the lower tertile of the sample were classified as “short” for
                    LTL. We also examined if having CRP levels above the clinical cutoff of &gt;3
                    mg/L was associated with increased odds for short LTL.</p>
        <p>Logistic regression analyses were used to examine if participants with high
                    levels of IL-6, TNF-α and CRP alone or in combination would be more likely
                    than participants with lower levels of these inflammatory markers to have short
                    LTL. In our first set of analyses, groups were not mutually exclusive, such that
                    the same individual could be represented in multiple groups if they had high
                    levels of IL-6, TNF-α or CRP. Based on the results of these analyses, we
                    excluded CRP from our model and conducted follow-up analyses to examine if the
                    odds for short LTL in participants with high levels of both IL-6 and TNF-α
                    was significantly higher than that of participants with high levels of only
                    IL-6, high levels of only TNF-α, or high levels of neither IL-6 nor
                    TNF-α. Thus, this second group of logistic regression analyses were
                    conducted on mutually exclusive groups. All models were run with the three
                    different sets of covariates as described in the covariates section. Analysis of
                    covariance was used to compare mean differences in base pairs of telomeres
                    between those with and without high levels of inflammatory markers.</p>
        <p>In order to compare characteristics of the sample by telomere length tertile we
                    performed analysis of variance and Kruskal-Wallis rank tests for continuous
                    variables, and chi-squared tests for categorical variables. In order to analyze
                    differences in LTL and cytokines by gender, linear regressions were used. Due to
                    unacceptable levels of skewness, the variables IL-6, TNF-α and CRP were
                    log-transformed when used in correlations and linear regressions. All analyses
                    were performed using Stata version 9.2 and SPSS version 18.0.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <p>The authors thank the Health ABC Study staff at the Pittsburgh and Memphis study
                sites and at the UCSF Coordinating Center for their assistance and patience, as well
                as the Health ABC Study participants for their time and efforts.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pone.0019687-Willeit1">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Willeit</surname><given-names>P</given-names></name><name name-style="western"><surname>Willeit</surname><given-names>J</given-names></name><name name-style="western"><surname>Mayr</surname><given-names>A</given-names></name><name name-style="western"><surname>Weger</surname><given-names>S</given-names></name><name name-style="western"><surname>Oberhollenzer</surname><given-names>F</given-names></name><etal/></person-group>
                    <year>2010</year>
                    <article-title>Telomere length and risk of incident cancer and cancer
                        mortality.</article-title>
                    <source>JAMA</source>
                    <volume>304</volume>
                    <fpage>69</fpage>
                    <lpage>75</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Fitzpatrick1">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Fitzpatrick</surname><given-names>AL</given-names></name><name name-style="western"><surname>Kronmal</surname><given-names>RA</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>JP</given-names></name><name name-style="western"><surname>Psaty</surname><given-names>BM</given-names></name><name name-style="western"><surname>Jenny</surname><given-names>NS</given-names></name><etal/></person-group>
                    <year>2007</year>
                    <article-title>Leukocyte telomere length and cardiovascular disease in the
                        Cardiovascular Health Study.</article-title>
                    <source>Am J Epidemiol</source>
                    <volume>165</volume>
                    <fpage>14</fpage>
                    <lpage>21</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-FarzanehFar1">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Farzaneh-Far</surname><given-names>R</given-names></name><name name-style="western"><surname>Cawthon</surname><given-names>RM</given-names></name><name name-style="western"><surname>Na</surname><given-names>B</given-names></name><name name-style="western"><surname>Browner</surname><given-names>WS</given-names></name><name name-style="western"><surname>Schiller</surname><given-names>NB</given-names></name><etal/></person-group>
                    <year>2008</year>
                    <article-title>Prognostic value of leukocyte telomere length in patients with
                        stable coronary artery disease: data from the Heart and Soul
                        Study.</article-title>
                    <source>Arterioscler Thromb Vasc Biol</source>
                    <volume>28</volume>
                    <fpage>1379</fpage>
                    <lpage>1384</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Epel1">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Epel</surname><given-names>ES</given-names></name><name name-style="western"><surname>Merkin</surname><given-names>SS</given-names></name><name name-style="western"><surname>Cawthon</surname><given-names>R</given-names></name><name name-style="western"><surname>Blackburn</surname><given-names>EH</given-names></name><name name-style="western"><surname>Adler</surname><given-names>NE</given-names></name><etal/></person-group>
                    <year>2009</year>
                    <article-title>The rate of leukocyte telomere shortening predicts mortality from
                        cardiovascular disease in elderly men.</article-title>
                    <source>Aging</source>
                    <volume>1</volume>
                    <fpage>81</fpage>
                    <lpage>88</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Carrero1">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Carrero</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Stenvinkel</surname><given-names>P</given-names></name><name name-style="western"><surname>Fellstrom</surname><given-names>B</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>AR</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>K</given-names></name><etal/></person-group>
                    <year>2008</year>
                    <article-title>Telomere attrition is associated with inflammation, low fetuin-A
                        levels and high mortality in prevalent haemodialysis
                        patients.</article-title>
                    <source>J Int Med</source>
                    <volume>263</volume>
                    <fpage>302</fpage>
                    <lpage>312</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Cawthon1">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Cawthon</surname><given-names>RM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>KR</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>E</given-names></name><name name-style="western"><surname>Sivatchenko</surname><given-names>A</given-names></name><name name-style="western"><surname>Kerber</surname><given-names>RA</given-names></name></person-group>
                    <year>2003</year>
                    <article-title>Association between telomere length in blood and mortality in
                        people aged 60 years or older.</article-title>
                    <source>Lancet</source>
                    <volume>361</volume>
                    <fpage>393</fpage>
                    <lpage>395</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Njajou1">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Njajou</surname><given-names>OT</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>WC</given-names></name><name name-style="western"><surname>Blackburn</surname><given-names>EH</given-names></name><name name-style="western"><surname>Newman</surname><given-names>AB</given-names></name><name name-style="western"><surname>Wu</surname><given-names>SH</given-names></name><etal/></person-group>
                    <year>2009</year>
                    <article-title>Association between telomere length, specific causes of death,
                        and years of healthy life in health, aging, and body composition, a
                        population-based cohort study.</article-title>
                    <source>J Gerontol A Biol Sci Med Sci</source>
                    <volume>64</volume>
                    <fpage>860</fpage>
                    <lpage>864</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Blackburn1">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Blackburn</surname><given-names>EH</given-names></name></person-group>
                    <year>1991</year>
                    <article-title>Structure and function of telomeres.</article-title>
                    <source>Nature</source>
                    <volume>350</volume>
                    <fpage>569</fpage>
                    <lpage>573</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Blackburn2">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Blackburn</surname><given-names>EH</given-names></name></person-group>
                    <year>2001</year>
                    <article-title>Switching and Signaling at the Telomere.</article-title>
                    <source>Cell</source>
                    <volume>106</volume>
                    <fpage>661</fpage>
                    <lpage>673</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Sahin1">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>E</given-names></name><name name-style="western"><surname>Colla</surname><given-names>S</given-names></name><name name-style="western"><surname>Liesa</surname><given-names>M</given-names></name><name name-style="western"><surname>Moslehi</surname><given-names>J</given-names></name><name name-style="western"><surname>Muller</surname><given-names>FL</given-names></name><etal/></person-group>
                    <year>2011</year>
                    <article-title>Telomere dysfunction induces metabolic and mitochondrial
                        compromise.</article-title>
                    <source>Nature</source>
                    <volume>470</volume>
                    <fpage>359</fpage>
                    <lpage>365</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Jaskelioff1">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Jaskelioff</surname><given-names>M</given-names></name><name name-style="western"><surname>Muller</surname><given-names>FL</given-names></name><name name-style="western"><surname>Paik</surname><given-names>JH</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>E</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><etal/></person-group>
                    <year>2011</year>
                    <article-title>Telomerase reactivation reverses tissue degeneration in aged
                        telomerase-deficient mice.</article-title>
                    <source>Nature</source>
                    <volume>469</volume>
                    <fpage>102</fpage>
                    <lpage>106</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Chung1">
        <label>12</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>HY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KW</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JS</given-names></name><name name-style="western"><surname>Yu</surname><given-names>BP</given-names></name></person-group>
                    <year>2002</year>
                    <article-title>Molecular inflammation hypothesis of aging based on the
                        anti-aging mechanism of calorie restriction.</article-title>
                    <source>Microsc Res Tech</source>
                    <volume>59</volume>
                    <fpage>264</fpage>
                    <lpage>272</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Chung2">
        <label>13</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>HY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JW</given-names></name><name name-style="western"><surname>Yu</surname><given-names>BP</given-names></name></person-group>
                    <year>2001</year>
                    <article-title>The Inflammation Hypothesis of Aging: molecular modulation by
                        calorie restriction.</article-title>
                    <source>Ann NY Acad Sci</source>
                    <volume>928</volume>
                    <fpage>327</fpage>
                    <lpage>335</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Kinouchi1">
        <label>14</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Kinouchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hiwatashi</surname><given-names>N</given-names></name><name name-style="western"><surname>Chida</surname><given-names>M</given-names></name><name name-style="western"><surname>Nagashima</surname><given-names>F</given-names></name><name name-style="western"><surname>Takagi</surname><given-names>S</given-names></name><etal/></person-group>
                    <year>1998</year>
                    <article-title>Telomere shortening in the colonic mucosa of patients with
                        ulcerative colitis.</article-title>
                    <source>J Gastroenterol</source>
                    <volume>33</volume>
                    <fpage>343</fpage>
                    <lpage>348</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Pradhan1">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Pradhan</surname><given-names>AD</given-names></name><name name-style="western"><surname>Manson</surname><given-names>JE</given-names></name><name name-style="western"><surname>Rifai</surname><given-names>N</given-names></name><name name-style="western"><surname>Buring</surname><given-names>JE</given-names></name><name name-style="western"><surname>Ridker</surname><given-names>PM</given-names></name></person-group>
                    <year>2001</year>
                    <article-title>C-reactive protein, interleukin 6, and risk of developing type-2
                        diabetes mellitus.</article-title>
                    <source>JAMA</source>
                    <volume>286</volume>
                    <fpage>327</fpage>
                    <lpage>334</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Libby1">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Libby</surname><given-names>P</given-names></name><name name-style="western"><surname>Ridker</surname><given-names>PM</given-names></name><name name-style="western"><surname>Maseri</surname><given-names>A</given-names></name></person-group>
                    <year>2002</year>
                    <article-title>Inflammation and atherosclerosis.</article-title>
                    <source>Circulation</source>
                    <volume>105</volume>
                    <fpage>1135</fpage>
                    <lpage>1143</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-WyssCoray1">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Wyss-Coray</surname><given-names>T</given-names></name></person-group>
                    <year>2006</year>
                    <article-title>Inflammation in Alzheimer disease: driving force, bystander or
                        beneficial response?</article-title>
                    <source>Nat Med</source>
                    <volume>12</volume>
                    <fpage>1005</fpage>
                    <lpage>1015</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Moss1">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Moss</surname><given-names>SF</given-names></name><name name-style="western"><surname>Blaser</surname><given-names>MJ</given-names></name></person-group>
                    <year>2005</year>
                    <article-title>Mechanisms of disease: inflammation and the origins of
                        cancer.</article-title>
                    <source>Nat Clin Prac Oncol</source>
                    <volume>2</volume>
                    <fpage>90</fpage>
                    <lpage>97</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Harris1">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>TB</given-names></name><name name-style="western"><surname>Ferrucci</surname><given-names>L</given-names></name><name name-style="western"><surname>Tracy</surname><given-names>RP</given-names></name><name name-style="western"><surname>Corti</surname><given-names>MC</given-names></name><name name-style="western"><surname>Wacholder</surname><given-names>S</given-names></name><etal/></person-group>
                    <year>1999</year>
                    <article-title>Associations of elevated interleukin-6 and C-reactive protein
                        levels with mortality in the elderly.</article-title>
                    <source>Am J Med</source>
                    <volume>106</volume>
                    <fpage>506</fpage>
                    <lpage>512</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Volpato1">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Volpato</surname><given-names>S</given-names></name><name name-style="western"><surname>Guralnik</surname><given-names>JM</given-names></name><name name-style="western"><surname>Ferrucci</surname><given-names>L</given-names></name><name name-style="western"><surname>Balfour</surname><given-names>J</given-names></name><name name-style="western"><surname>Chaves</surname><given-names>P</given-names></name><etal/></person-group>
                    <year>2001</year>
                    <article-title>Cardiovascular disease, interleukin-6, and risk of mortality in
                        older women: The Women's Health and Aging Study.</article-title>
                    <source>Circulation</source>
                    <volume>103</volume>
                    <fpage>947</fpage>
                    <lpage>953</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Slattery1">
        <label>21</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Slattery</surname><given-names>ML</given-names></name><name name-style="western"><surname>Curtin</surname><given-names>K</given-names></name><name name-style="western"><surname>Baumgartner</surname><given-names>R</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>C</given-names></name><name name-style="western"><surname>Byers</surname><given-names>T</given-names></name><etal/></person-group>
                    <year>2007</year>
                    <article-title>IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast
                        cancer risk in women living in the southwestern United
                        States.</article-title>
                    <source>Cancer Epidemiol Biomarkers Prev</source>
                    <volume>16</volume>
                    <fpage>747</fpage>
                    <lpage>755</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Aviv1">
        <label>22</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Aviv</surname><given-names>A</given-names></name></person-group>
                    <year>2004</year>
                    <article-title>Telomeres and human aging: facts and fibs.</article-title>
                    <source>Sci Aging Knowledge Environ</source>
                    <volume>2004</volume>
                    <fpage>pe43</fpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Jaiswal1">
        <label>23</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Jaiswal</surname><given-names>M</given-names></name><name name-style="western"><surname>LaRusso</surname><given-names>NF</given-names></name><name name-style="western"><surname>Burgart</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Gores</surname><given-names>GJ</given-names></name></person-group>
                    <year>2000</year>
                    <article-title>Inflammatory cytokines induce DNA damage and inhibit DNA repair
                        in cholangiocarcinoma cells by a nitric oxide-dependent
                        mechanism.</article-title>
                    <source>Cancer Res</source>
                    <volume>60</volume>
                    <fpage>184</fpage>
                    <lpage>190</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Xu1">
        <label>24</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><name name-style="western"><surname>Erickson</surname><given-names>S</given-names></name><name name-style="western"><surname>Szeps</surname><given-names>M</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>A</given-names></name><name name-style="western"><surname>Sangfelt</surname><given-names>O</given-names></name><etal/></person-group>
                    <year>2000</year>
                    <article-title>Interferon alpha down-regulates telomerase reverse transcriptase
                        and telomerase activity in human malignant and nonmalignant hematopoietic
                        cells.</article-title>
                    <source>Blood</source>
                    <volume>96</volume>
                    <fpage>4313</fpage>
                    <lpage>4318</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Parish1">
        <label>25</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Parish</surname><given-names>ST</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JE</given-names></name><name name-style="western"><surname>Effros</surname><given-names>RB</given-names></name></person-group>
                    <year>2009</year>
                    <article-title>Modulation of T lymphocyte replicative senescence via TNF-{alpha}
                        inhibition: role of caspase-3.</article-title>
                    <source>J Immunol</source>
                    <volume>182</volume>
                    <fpage>4237</fpage>
                    <lpage>4243</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Akiyama1">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Akiyama</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>O</given-names></name><name name-style="western"><surname>Hideshima</surname><given-names>T</given-names></name><name name-style="western"><surname>Yanagisawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Yokoi</surname><given-names>K</given-names></name><etal/></person-group>
                    <year>2004</year>
                    <article-title>TNF[alpha] induces rapid activation and nuclear
                        translocation of telomerase in human lymphocytes.</article-title>
                    <source>Biochem Biophys Res Commun</source>
                    <volume>316</volume>
                    <fpage>528</fpage>
                    <lpage>532</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Greider1">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Greider</surname><given-names>CW</given-names></name><name name-style="western"><surname>Blackburn</surname><given-names>EH</given-names></name></person-group>
                    <year>1989</year>
                    <article-title>A telomeric sequence in the RNA of Tetrahymena telomerase
                        required for telomere repeat synthesis.</article-title>
                    <source>Nature</source>
                    <volume>337</volume>
                    <fpage>331</fpage>
                    <lpage>337</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Rodier1">
        <label>28</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Rodier</surname><given-names>F</given-names></name><name name-style="western"><surname>Coppe</surname><given-names>JP</given-names></name><name name-style="western"><surname>Patil</surname><given-names>CK</given-names></name><name name-style="western"><surname>Hoeijmakers</surname><given-names>WA</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>DP</given-names></name><etal/></person-group>
                    <year>2009</year>
                    <article-title>Persistent DNA damage signalling triggers senescence-associated
                        inflammatory cytokine secretion.</article-title>
                    <source>Nat Cell Biol</source>
                    <volume>11</volume>
                    <fpage>973</fpage>
                    <lpage>979</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Krtolica1">
        <label>29</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Krtolica</surname><given-names>A</given-names></name><name name-style="western"><surname>Parrinello</surname><given-names>S</given-names></name><name name-style="western"><surname>Lockett</surname><given-names>S</given-names></name><name name-style="western"><surname>Desprez</surname><given-names>PY</given-names></name><name name-style="western"><surname>Campisi</surname><given-names>J</given-names></name></person-group>
                    <year>2001</year>
                    <article-title>Senescent fibroblasts promote epithelial cell growth and
                        tumorigenesis: a link between cancer and aging.</article-title>
                    <source>Proc Natl Acad Sci U S A</source>
                    <volume>98</volume>
                    <fpage>12072</fpage>
                    <lpage>12077</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Aikata1">
        <label>30</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Aikata</surname><given-names>H</given-names></name><name name-style="western"><surname>Takaishi</surname><given-names>H</given-names></name><name name-style="western"><surname>Kawakami</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>S</given-names></name><name name-style="western"><surname>Kitamoto</surname><given-names>M</given-names></name><etal/></person-group>
                    <year>2000</year>
                    <article-title>Telomere reduction in human liver tissues with age and chronic
                        inflammation.</article-title>
                    <source>Exp Cell Res</source>
                    <volume>256</volume>
                    <fpage>578</fpage>
                    <lpage>582</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Steer1">
        <label>31</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Steer</surname><given-names>SE</given-names></name><name name-style="western"><surname>Williams</surname><given-names>FM</given-names></name><name name-style="western"><surname>Kato</surname><given-names>B</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>JP</given-names></name><name name-style="western"><surname>Norman</surname><given-names>PJ</given-names></name><etal/></person-group>
                    <year>2007</year>
                    <article-title>Reduced telomere length in rheumatoid arthritis is independent of
                        disease activity and duration.</article-title>
                    <source>Ann Rheum Dis</source>
                    <volume>66</volume>
                    <fpage>476</fpage>
                    <lpage>480</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Houben1">
        <label>32</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Houben</surname><given-names>JM</given-names></name><name name-style="western"><surname>Mercken</surname><given-names>EM</given-names></name><name name-style="western"><surname>Ketelslegers</surname><given-names>HB</given-names></name><name name-style="western"><surname>Bast</surname><given-names>A</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>EF</given-names></name><etal/></person-group>
                    <year>2009</year>
                    <article-title>Telomere shortening in chronic obstructive pulmonary
                        disease.</article-title>
                    <source>Respir Med</source>
                    <volume>103</volume>
                    <fpage>230</fpage>
                    <lpage>236</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Pearson1">
        <label>33</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Pearson</surname><given-names>TA</given-names></name><name name-style="western"><surname>Mensah</surname><given-names>GA</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>RW</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>JL</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>RO</given-names><suffix>3rd</suffix></name><etal/></person-group>
                    <year>2003</year>
                    <article-title>Markers of inflammation and cardiovascular disease: application
                        to clinical and public health practice: A statement for healthcare
                        professionals from the Centers for Disease Control and Prevention and the
                        American Heart Association.</article-title>
                    <source>Circulation</source>
                    <volume>107</volume>
                    <fpage>499</fpage>
                    <lpage>511</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Castell1">
        <label>34</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Castell</surname><given-names>JV</given-names></name><name name-style="western"><surname>Gomez-Lechon</surname><given-names>MJ</given-names></name><name name-style="western"><surname>David</surname><given-names>M</given-names></name><name name-style="western"><surname>Andus</surname><given-names>T</given-names></name><name name-style="western"><surname>Geiger</surname><given-names>T</given-names></name><etal/></person-group>
                    <year>1989</year>
                    <article-title>Interleukin-6 is the major regulator of acute phase protein
                        synthesis in adult human hepatocytes.</article-title>
                    <source>FEBS Lett</source>
                    <volume>242</volume>
                    <fpage>237</fpage>
                    <lpage>239</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Castell2">
        <label>35</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Castell</surname><given-names>JV</given-names></name><name name-style="western"><surname>Gomez-Lechon</surname><given-names>MJ</given-names></name><name name-style="western"><surname>David</surname><given-names>M</given-names></name><name name-style="western"><surname>Hirano</surname><given-names>T</given-names></name><name name-style="western"><surname>Kishimoto</surname><given-names>T</given-names></name><etal/></person-group>
                    <year>1988</year>
                    <article-title>Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the
                        synthesis of acute phase proteins in human hepatocytes.</article-title>
                    <source>FEBS Lett</source>
                    <volume>232</volume>
                    <fpage>347</fpage>
                    <lpage>350</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Weinhold1">
        <label>36</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Weinhold</surname><given-names>B</given-names></name><name name-style="western"><surname>Bader</surname><given-names>A</given-names></name><name name-style="western"><surname>Poli</surname><given-names>V</given-names></name><name name-style="western"><surname>Ruther</surname><given-names>U</given-names></name></person-group>
                    <year>1997</year>
                    <article-title>Interleukin-6 is necessary, but not sufficient, for induction of
                        the humanC-reactive protein gene in vivo.</article-title>
                    <source>Biochem J</source>
                    <volume>325</volume>
                    <issue>Pt 3</issue>
                    <fpage>617</fpage>
                    <lpage>621</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Calabro1">
        <label>37</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Calabro</surname><given-names>P</given-names></name><name name-style="western"><surname>Willerson</surname><given-names>JT</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>ET</given-names></name></person-group>
                    <year>2003</year>
                    <article-title>Inflammatory cytokines stimulated C-reactive protein production
                        by human coronary artery smooth muscle cells.</article-title>
                    <source>Circulation</source>
                    <volume>108</volume>
                    <fpage>1930</fpage>
                    <lpage>1932</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Coppe1">
        <label>38</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Coppe</surname><given-names>JP</given-names></name><name name-style="western"><surname>Patil</surname><given-names>CK</given-names></name><name name-style="western"><surname>Rodier</surname><given-names>F</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>DP</given-names></name><etal/></person-group>
                    <year>2008</year>
                    <article-title>Senescence-associated secretory phenotypes reveal
                        cell-nonautonomous functions of oncogenic RAS and the p53 tumor
                        suppressor.</article-title>
                    <source>PLoS Biol</source>
                    <volume>6</volume>
                    <fpage>2853</fpage>
                    <lpage>2868</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Lin1">
        <label>39</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>MT</given-names></name><name name-style="western"><surname>Juan</surname><given-names>CY</given-names></name><name name-style="western"><surname>Chang</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>ML</given-names></name></person-group>
                    <year>2001</year>
                    <article-title>IL-6 inhibits apoptosis and retains oxidative DNA lesions in
                        human gastric cancer AGS cells through up-regulation of anti-apoptotic gene
                        mcl-1.</article-title>
                    <source>Carcinogenesis</source>
                    <volume>22</volume>
                    <fpage>1947</fpage>
                    <lpage>1953</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Mangan1">
        <label>40</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Mangan</surname><given-names>DF</given-names></name><name name-style="western"><surname>Wahl</surname><given-names>SM</given-names></name></person-group>
                    <year>1991</year>
                    <article-title>Differential regulation of human monocyte programmed cell death
                        (apoptosis) by chemotactic factors and pro-inflammatory
                        cytokines.</article-title>
                    <source>J Immunol</source>
                    <volume>147</volume>
                    <fpage>3408</fpage>
                    <lpage>3412</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Elliott1">
        <label>41</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Elliott</surname><given-names>P</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>JC</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>R</given-names></name><name name-style="western"><surname>Hopewell</surname><given-names>JC</given-names></name><etal/></person-group>
                    <year>2009</year>
                    <article-title>Genetic Loci associated with C-reactive protein levels and risk
                        of coronary heart disease.</article-title>
                    <source>JAMA</source>
                    <volume>302</volume>
                    <fpage>37</fpage>
                    <lpage>48</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Kritchevsky1">
        <label>42</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Kritchevsky</surname><given-names>SB</given-names></name><name name-style="western"><surname>Cesari</surname><given-names>M</given-names></name><name name-style="western"><surname>Pahor</surname><given-names>M</given-names></name></person-group>
                    <year>2005</year>
                    <article-title>Inflammatory markers and cardiovascular health in older
                        adults.</article-title>
                    <source>Cardiovasc Res</source>
                    <volume>66</volume>
                    <fpage>265</fpage>
                    <lpage>275</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Cesari1">
        <label>43</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Cesari</surname><given-names>M</given-names></name><name name-style="western"><surname>Penninx</surname><given-names>BW</given-names></name><name name-style="western"><surname>Newman</surname><given-names>AB</given-names></name><name name-style="western"><surname>Kritchevsky</surname><given-names>SB</given-names></name><name name-style="western"><surname>Nicklas</surname><given-names>BJ</given-names></name><etal/></person-group>
                    <year>2003</year>
                    <article-title>Inflammatory markers and cardiovascular disease: The Health,
                        Aging and Body Composition [Health ABC] Study.</article-title>
                    <source>Am J Cardiol</source>
                    <volume>92</volume>
                    <fpage>522</fpage>
                    <lpage>528</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Nishida1">
        <label>44</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Nishida</surname><given-names>H</given-names></name><name name-style="western"><surname>Horio</surname><given-names>T</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Iwashima</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tokudome</surname><given-names>T</given-names></name><etal/></person-group>
                    <year>2011</year>
                    <article-title>Interleukin-6 as an independent predictor of future
                        cardiovascular events in high-risk Japanese patients: comparison with
                        C-reactive protein.</article-title>
                    <source>Cytokine</source>
                    <volume>53</volume>
                    <fpage>342</fpage>
                    <lpage>346</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Aviv2">
        <label>45</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Aviv</surname><given-names>A</given-names></name></person-group>
                    <year>2009</year>
                    <article-title>Commentary: Raising the bar on telomere
                        epidemiology.</article-title>
                    <source>Int J Epidemiol</source>
                    <volume>38</volume>
                    <fpage>1735</fpage>
                    <lpage>1736</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Aviv3">
        <label>46</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Aviv</surname><given-names>A</given-names></name></person-group>
                    <year>2008</year>
                    <article-title>The epidemiology of human telomeres: faults and
                        promises.</article-title>
                    <source>J Gerontol A Biol Sci Med Sci</source>
                    <volume>63</volume>
                    <fpage>979</fpage>
                    <lpage>983</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Cawthon2">
        <label>47</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Cawthon</surname><given-names>RM</given-names></name></person-group>
                    <year>2002</year>
                    <article-title>Telomere measurement by quantitative PCR.</article-title>
                    <source>Nucl Acids Res</source>
                    <volume>30</volume>
                    <fpage>e47</fpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Njajou2">
        <label>48</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Njajou</surname><given-names>OT</given-names></name><name name-style="western"><surname>Blackburn</surname><given-names>EH</given-names></name><name name-style="western"><surname>Pawlikowska</surname><given-names>L</given-names></name><name name-style="western"><surname>Mangino</surname><given-names>M</given-names></name><name name-style="western"><surname>Damcott</surname><given-names>CM</given-names></name><etal/></person-group>
                    <year>2010</year>
                    <article-title>A common variant in the telomerase RNA component is associated
                        with short telomere length.</article-title>
                    <source>PLoS ONE</source>
                    <volume>5</volume>
                    <fpage>e13048</fpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Cawthon3">
        <label>49</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Cawthon</surname><given-names>RM</given-names></name></person-group>
                    <year>2009</year>
                    <article-title>Telomere length measurement by a novel monochrome multiplex
                        quantitative PCR method.</article-title>
                    <source>Nucleic Acids Res</source>
                    <volume>37</volume>
                    <fpage>e21</fpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Steyerberg1">
        <label>50</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Steyerberg</surname><given-names>EW</given-names></name><name name-style="western"><surname>Eijkemans</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Harrell</surname><given-names>FE</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Habbema</surname><given-names>JD</given-names></name></person-group>
                    <year>2001</year>
                    <article-title>Prognostic modeling with logistic regression analysis: in search
                        of a sensible strategy in small data sets.</article-title>
                    <source>Med Decis Making</source>
                    <volume>21</volume>
                    <fpage>45</fpage>
                    <lpage>56</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Sun1">
        <label>51</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>GW</given-names></name><name name-style="western"><surname>Shook</surname><given-names>TL</given-names></name><name name-style="western"><surname>Kay</surname><given-names>GL</given-names></name></person-group>
                    <year>1996</year>
                    <article-title>Inappropriate use of bivariable analysis to screen risk factors
                        for use in multivariable analysis.</article-title>
                    <source>J Clin Epidemiol</source>
                    <volume>49</volume>
                    <fpage>907</fpage>
                    <lpage>916</lpage>
                </element-citation>
      </ref>
      <ref id="pone.0019687-Pahor1">
        <label>52</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Pahor</surname><given-names>M</given-names></name><name name-style="western"><surname>Chrischilles</surname><given-names>EA</given-names></name><name name-style="western"><surname>Guralnik</surname><given-names>JM</given-names></name><name name-style="western"><surname>Brown</surname><given-names>SL</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>RB</given-names></name><etal/></person-group>
                    <year>1994</year>
                    <article-title>Drug data coding and analysis in epidemiologic
                        studies.</article-title>
                    <source>Eur J Epidemiol</source>
                    <volume>10</volume>
                    <fpage>405</fpage>
                    <lpage>411</lpage>
                </element-citation>
      </ref>
    </ref-list>
    
  </back>
</article>